secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-031886
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set
------------------------------------------------------------------------------

- Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.
- Cash $18.1M at June 30 from $26.4M at Dec 31; runway expected to fund operations for next 12 months.
- Topline results from Phase 2a influenza A human challenge study (oral CC-42344) expected in 2025.
- In vitro data shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein recently found in U.S. dairy cows.
- Topline Phase 1 results for pan-coronavirus/norovirus oral CDI-988 expected late 2024 / early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224031886/0001493152-24-031886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224031886/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer